C-reactive protein as a potential predictive biomarker for kidney cancer
A recent study published in Science Direct describes how a [...]
Immunotherapy combinations standard of care for advanced kidney cancer
In 2015, the standard treatment for most patients with advanced [...]
Individualised treatment plans improve outcomes for kidney cancer
Over the past couple of years there have been several [...]
Nivolumab/ipilimumab combination extends treatment-free survival in kidney cancer patients
Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab have [...]
Predictive biomarkers needed for combination treatments in kidney cancer
In this interview with OncLive, Dr Ulka Vaishampayan from Wayne [...]
PARP inhibitors, vaccines and combination therapies for kidney cancer
In this interview with OncLive, professor Sumanta Kumar Pal from [...]
Renal mass biopsy in the management of kidney cancer
A review of the evolving field of the management of [...]
Bone-targeted therapies may improve survival in metastatic kidney cancer patients
A recent study published in the journal Translational Oncology suggests [...]
Body mass index may impact survival in patients with kidney cancer
A recent paper published in the journal Lancet Oncology provides [...]
One Cancer Voice
Last month, 30 cancer charities came together to develop a [...]
